DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

IQV·IQVIA Holdings Inc.

$.
-. (-.%)
After Hours
High
$211.01
Open
$211.00
Market Cap
34.64B
52W High
$247.05
Low
$206.73
P. Close
$207.85
P/E
25.01
52W Low
$154.50
Fwd P/E
14.61
DailyIQ Est.
$237.37
Technical Score (1D)
86
BUY
News Sentiment
59
BULLISH
IQVIA’s latest earnings report shows a trailing 12‑month free cash flow margin of 12.7%, underscoring the company’s robust liquidity base. The margin indicates that the firm is generating ample cash, but analysts caution that the real value will depend on how efficiently that cash is deployed into growth initiatives. This development matters for the next 1–10 trading days because it sets the stage for the company’s upcoming earnings guidance, which will reveal whether the cash is earmarked for acquisitions, share buybacks, or R&D expansion. At the same time, a new long position from Artisan Partners, announced 17 hours ago, highlights investor confidence in IQVIA’s AI capabilities and its resilience amid potential disruptions in the clinical research sector. The partnership bet signals that market participants expect AI integration to drive operational efficiencies and cost savings, which could translate into higher margins. The convergence of strong cash flow and a bullish AI narrative suggests that IQVIA may be positioned to accelerate its technology roadmap without compromising financial stability. Traders should watch the next earnings release for explicit guidance on cash utilization, as well as any updates on AI‑driven projects and potential acquisitions. Additionally, monitoring the company’s competitive positioning within the clinical research space will be key, as any shift in market share could affect its long‑term growth prospects. Finally, keep an eye on broader sector dynamics, such as regulatory changes or shifts in drug development timelines, which could influence IQVIA’s revenue streams and the effectiveness of its AI initiatives.
Earnings Summary
IQVIA Holdings, Inc. is a global provider of technology, analytics, and services to the life sciences and healthcare industries, delivering integrated solutions across drug development and commercialization. Operating through Technology & Analytics, Research & Development, and Contract Sales & Medical segments, the company supports pharmaceutical, biotechnology, and medical device clients in a rapidly evolving healthcare sector. In the most recent quarters, Q3 2025 saw EPS of $3.00 versus an estimate of $2.98, a beat, while revenue climbed to $4.10 billion, continuing a steady upward trajectory; Q1 2026, however, reported EPS of $2.90 against an estimate of $3.04 and revenue of $4.15 billion versus an estimate of $4.25 billion, marking a miss after a series of prior successes. Over the past year, EPS rose from $2.70 in Q1 2025 to $2.90 in Q1 2026, a roughly 7.4% increase, and revenue grew from $3.83 billion to $4.15 billion, about 8.5% YoY, underscoring consistent top‑line expansion even as earnings slipped in the latest quarter. The company has consistently beat analyst estimates in four of the last five quarters, with revenue growth persisting despite the Q1 2026 EPS miss, reflecting a resilient business model. Recent news highlights ICON’s strategic pivot toward expanding its contract research organization services, a move expected to broaden revenue streams and deepen its footprint in the biopharma pipeline, while multiple research houses have raised price targets on the back of stronger data‑analytics and cloud offerings, signaling heightened investor confidence. Investors should watch for any upward revisions to earnings guidance that may accompany new partnership deals or large‑scale contracts, monitor regulatory updates that could affect clinical trial timelines, and track competitor responses in the CRO space, as these factors will likely shape the company’s near‑term valuation and earnings trajectory.

EPS

EstBeatMiss
$2.56$2.72$2.88$3.03$3.19Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.04 - -
Q1'26$3.04$2.90-4.7%
Q3'25$2.98$3.00+0.8%
Q2'25$2.77$2.81+1.4%
Q1'25$2.63$2.70+2.6%
Q4'24$3.11$3.12+0.4%

Revenue

EstBeatMiss
$3.8B$3.9B$4.1B$4.3B$4.4BQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.3B - -
Q1'26$4.2B$4.2B-2.3%
Q3'25 - $4.1B -
Q2'25 - $4.0B -
Q1'25 - $3.8B -
Q4'24 - $4.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

IQV Stock Snapshot

IQV is currently trading at $207.00, giving IQVIA Holdings Inc. a market cap of 34.64B and a P/E ratio of 25.0. Today's range spans $206.73–$211.01, with shares opening at $211.00 and moving down $0.85 (0.4%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 59/100.

Over the past year IQV has traded between $154.50 and $247.05 - the current price is +34.0% off the 52-week low and -16.2% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $229.63 (range $200.00–$284.00), implying upside of +10.9%.

If you're looking for bullish momentum in Healthcare, IQV is putting up the numbers: 86/100 technical score, BUY signal, neutral sentiment at 59/100. Price: $207.00 (in the middle of its 52-week range). (P/E: 25.0) The 34.64B market cap keeps it in play for institutional position sizes, and the $154.50–$247.05 annual range shows this stock can make real moves when it gets directional conviction behind it.

What makes IQV's BUY setup (86/100) particularly actionable at 34.64B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $207.00 (in the middle of its 52-week range in $154.50–$247.05), with sentiment running neutral at 59/100, the setup rewards conviction-sized positioning more than it does speculative small bets.